Add BrightSurf on Google Email

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

A global research network, led by ASAP and MJFF, is expanding its efforts to map the biological blueprint of Parkinson's disease and develop a standardized toolkit of global research resources. This expansion aims to accelerate the development of personalized therapies by understanding the disease's inherent heterogeneity.

Scientists map ‘energy network patterns’ in brain to track Alzheimer’s disease across disease spectrum

Researchers at Indiana University School of Medicine developed a new method to analyze brain energy network patterns, revealing insights into Alzheimer's disease progression. The study found that brain networks reorganize as the disease progresses, with memory and language functions showing increased metabolic demand in early stages.

SourceIndiana University·JournalAlzheimer s & Dementia·DateApr 28, 2026

Re-conceptualizing Parkinson’s disease as a lifelong neurobiological trajectory: A framework for prevention

A new review proposes a prevention-focused framework for understanding Parkinson's disease risk, highlighting the role of early-life vulnerability, environmental exposures, and resilience factors. The study suggests that susceptibility to PD may begin earlier in life through interactions between biology and environment.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalNeuroprotection·TypeLiterature review·DateApr 28, 2026

Texas Children’s researcher awarded $6. 7 million NIH grant to accelerate Alzheimer’s drug discovery and advance new therapies

Researchers will use DNA-encoded chemical libraries and artificial intelligence to screen hundreds of millions of potential drug compounds, identifying those most likely to succeed in treating Alzheimer's. The project aims to shorten the timeline for identifying new treatments, bringing them to patients faster and with greater precision.

Mini brain-like structures grown in lab may help scientists treat, diagnose and stage Alzheimer’s disease

Researchers from Johns Hopkins Medicine have developed mini brain-like structures grown in the lab that could be used to evaluate how patients with Alzheimer's disease respond to certain drugs. The study found that tiny particles secreted by these brain tissues may contain cellular information that could help scientists find new biomar...

SourceJohns Hopkins Medicine·JournalAlzheimer’s & Dementia·DateApr 20, 2026

Anti-amyloid Alzheimer’s drugs show no clinically meaningful effect

A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateApr 15, 2026

Scientists reverse brain aging, with a nasal spray

Researchers developed a nasal spray that reversibly reduces brain inflammation, restores cellular power plants, and improves memory. The treatment bypasses the brain's protective shield through intranasal delivery, suppressing chronic inflammation and promoting successful brain aging.

SourceTexas A&M University·JournalJournal of Extracellular Vesicles·DateApr 14, 2026

New drug combination doubles down on Alzheimer's treatments

Researchers at the University of Waterloo have discovered a safer and more effective way to treat Alzheimer's disease by combining anti-amyloid antibodies with molecules found in grapes, berries, peanuts, and turmeric. This combination approach neutralizes amyloid protein clumping in the brain, leading to better outcomes.

SourceUniversity of Waterloo·JournalACS Chemical Neuroscience·TypeExperimental study·DateApr 9, 2026

Chinese Medical Journal review illuminates the multifaceted role of LRRK2 in health and disease

The review highlights LRRK2's diverse cellular functions and pathogenic mechanisms in various diseases, including Parkinson's disease and inflammatory disorders. Therapeutic strategies targeting LRRK2, such as kinase inhibitors and emerging approaches like PROTACs and gene therapy, show promise for correcting cellular imbalances and re...

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateApr 1, 2026

Answering an urgent need

The Linda and Mike Mussallem Foundation has donated to USC's Keck School of Medicine to enhance clinical trials for individuals with Down syndrome at risk for Alzheimer's. This will increase domestic and international sites, accelerating the development of treatments specifically for this population.

Cognito Therapeutics and Ochsner Health launch Brain Health Collaboratory to advance new care models for Alzheimer’s disease

The Brain Health Collaboratory aims to accelerate the discovery, validation, and delivery of non-invasive neuroprotective therapies for cognitive decline and Alzheimer's disease. Cognito Therapeutics' Spectris technology platform will be combined with Ochsner's clinical network to explore new approaches to brain health care delivery.

New blood marker reduces the risk of a false diagnosis of Alzheimer’s disease

Researchers at Lund University have developed a new blood marker that significantly improves the accuracy of Alzheimer's diagnosis. The study found that combining two biomarkers, p-tau217 and eMTBR-tau243, can identify people with established Alzheimer's disease with an accuracy rate of around 80%. This breakthrough reduces false posit...

SourceLund University·JournalThe Lancet Neurology·TypeObservational study·DateMar 23, 2026

New research shows how to diagnose people with Alzheimer’s plus a hard-to-identify dementia type

Researchers found that patients with both conditions exhibited different neuropsychiatric symptoms, which could inform diagnosis and treatment plans. The study's findings may help clinicians better understand the complex disease course of patients with multiple disorders, including Alzheimer's and frontotemporal lobar degeneration.

SourceBrown University·JournalNeurology·TypeData/statistical analysis·DateMar 16, 2026

New study on early Parkinson’s disease progression highlights vital role of patient focused drug development and real-world impacts

A new study found that functional impairment worsened over time in individuals with early Parkinson's disease, despite plateaued symptoms, with gait, balance, and posture being the most bothersome issues. The study's results underscore the importance of incorporating real-world measures of disease progression in clinical trial design.

Many patients want to talk about their faith. Neurologists often don't know how.

Patients with neurological diseases face profound questions about identity, purpose, and meaning, but neurologists often lack training and tools to address these concerns. A new paper offers practical strategies for incorporating spiritual assessment into routine neurological care.

SourceUniversity of California - Los Angeles Health Sciences·JournalNeurology Clinical Practice·TypeCommentary/editorial·DateMar 9, 2026